202 related articles for article (PubMed ID: 24929883)
1. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.
Czarnowicki T; Linkner RV; Suárez-Fariñas M; Ingber A; Lebwohl M
J Am Acad Dermatol; 2014 Nov; 71(5):954-959.e1. PubMed ID: 24929883
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
Lebwohl M; Yoles A; Lombardi K; Lou W
J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
[TBL] [Abstract][Full Text] [Related]
5. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
[No Abstract] [Full Text] [Related]
6. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
Lee CS; Koo J
J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies.
Bernhard J; Whitmore C; Guzzo C; Kantor I; Kalb RE; Ellis C; Urbach F; Schwartzel EH; Gibson JR
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1170-4. PubMed ID: 1757612
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and topical therapy.
Lebwohl M
Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis.
Goldberg B; Hartdegen R; Presbury D; Smith EH; Yawalkar S
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1145-8. PubMed ID: 1757605
[TBL] [Abstract][Full Text] [Related]
12. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
Bhatia N; Stein Gold L; Kircik LH; Schreiber R
J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
[TBL] [Abstract][Full Text] [Related]
13. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
[TBL] [Abstract][Full Text] [Related]
14. Clobetasol propionate for psoriasis: are ointments really more potent?
Warino L; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
[TBL] [Abstract][Full Text] [Related]
15. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
17. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
18. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.
Sugarman JL; Weiss JS; Tanghetti EA; Soung J; Yamauchi PS; Lin T; Harris S; Martin G; Pillai R
Cutis; 2019 Feb; 103(2):111-116. PubMed ID: 30893392
[TBL] [Abstract][Full Text] [Related]
20. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
